课题基金 / 基金详情

Immunoferroptosis: a novel mechanism and promising therapeutic strategy in lung transplantation.

Immunoferroptosis: a novel mechanism and promising therapeutic strategy in lung transplantation.
免疫铁死亡:肺移植中的一种新机制和有前途的治疗策略。
批准号:
505756743
负责人:
Privatdozent Dr. Alexey Dashkevich, Ph.D.
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Privatdozent Dr. Alexey Dashkevich, Ph.D.的其他基金

相似基金

相关文献

中文摘要
翻译
肺移植是终末期肺病患者的最后手段。肺移植受者的健康状况得到改善。不幸的是,肺移植在所有实体器官移植中表现出最差的长期存活率。尽管手术技术、供体选择、肺保存和免疫抑制疗法已经取得进展,肺移植后的中位生存期仅略有增加,成人仅为6.7年。移植后存活1年以上的肺受体长期生存的最大威胁是慢性肺同种异体移植物功能障碍(chronic lung allograft dysfunction, CLAD)的发生和进展,包括三种表型:闭塞性细支气管炎综合征(BOS)、中性粒细胞可逆性同种异体移植物功能障碍和限制性同种异体移植物综合征,每一种表型都以气道阻塞或受限为特征,并且对免疫抑制基本无反应。在所描述的各种细胞死亡途径中,铁死亡是一种ros依赖的细胞死亡形式,与两个主要的生化特征有关,即铁积累和脂质过氧化,导致半胱天冬酶和坏死体无关的细胞死亡。缺血再灌注损伤(IRI)是发生慢性同种异体肺移植排斥反应的危险因素之一,最近的出版物将IRI的严重程度与铁上吊现象联系起来。然而,慢性排斥肺中诱导铁细胞死亡的分子机制及其对BOS发展的贡献仍不清楚,也不清楚其作为急需的治疗靶点的潜力。在这里,我们的目的是阐明免疫上铁炎作为慢性排斥肺同种异体移植物中协调CLAD和BOS发展的主要细胞死亡的特定机制,并描述它们作为患者BOS生物标志物的潜力,以改善早期诊断。Alexey Dashkevich博士作为临床医生和Ali Önder Yildirim博士作为基础研究人员的相互应用应该强制执行实验结果对临床相关问题的含义。
英文摘要
Lung transplantation is the last resort for patients with end-stage lung diseases. The lung transplant recipients benefit from this procedure with health improvement. Unfortunately, lung transplantation displays the worst long-term survival in all solid organ transplantation. Although surgical technique, donor selection, lung preservation, and immunosuppressive therapies have been advanced, the median survival after lung transplantation has increased only slightly, to just 6.7 years in adults. The greatest threat to long-term survival for lung recipients who have survived more than one year post-transplantation is the onset and progression of chronic lung allograft dysfunction (CLAD), which includes three phenotypes: bronchiolitis obliterans syndrome (BOS), neutrophilic reversible allograft dysfunction, and restrictive allograft syndrome, and each of them is characterized either by airway obstruction or restriction, and is largely unresponsive to immunosuppression.Among various cell death pathways described, ferroptosis is a ROS-dependent form of cell death associated with two main biochemical characteristics, namely iron accumulation and lipid peroxidation, leading to caspase- and necrosome-independent cell death. Ischemia-reperfusion injury (IRI) is one of the risk factors for developing chronic lung allograft rejection and recent publications are linking the severity of IRI with the phenomenon of ferroptosis. However, the molecular mechanisms underlying the induction of ferroptotic cell death in the chronically rejecting lung and its contribution to BOS development remains unknown along with its potential as a much-needed therapeutic target. Here, we aim to elucidate the contribution of specific mechanisms of immunoferroptotis as the primary cell death in orchestrating CLAD and BOS development in the chronically rejecting lung allografts and to delineate their potential as BOS biomarkers in patient to improve an early diagnosis.The mutual application of Dr. Alexey Dashkevich as a clinician and Dr. Ali Önder Yildirim as a basic researcher should enforce the implication of the bench findings to the clinically relevant questions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lymphatic endothelium as a new immunomodulatory target in lung transplantation
Molecular And Gene Therapy For Organ Transplantation: Targeting Of Lymph Angiogenesis As a New Immunomodulatory Approach In Heart Transplantation
  • 批准号:
    201579246
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $0.0万
  • 财政年份:
    2011
  • 负责人:
    Privatdozent Dr. Alexey Dashkevich, Ph.D.
  • 依托单位:
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
miR-2796和novel_13靶向磷脂酶C基因调控Q烟粉虱高温耐受性的分子机制
  • 批准号:
    32402377
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2024
  • 负责人:
    戴恬美
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位: